Last Updated : April 19, 2021
Details
FilesGeneric Name:
Isatuximab
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Sanofi Genzyme
Brand Name:
Sarclisa
Project Line:
Reimbursement Review
Project Number:
PC0220-000
NOC Status at Filing:
Post NOC
Strength:
100mg and 500mg
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Review Status:
Notification to Implement Issued
Sponsor:
Sanofi Genzyme
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 19, 2021